Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8058 USD | +2.65% | +0.60% | -32.85% |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 2.66M 3.64M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.1
x | P/E ratio 2024 * |
-0.11
x | Employees | 18 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.63% |
Latest transcript on Eloxx Pharmaceuticals, Inc.
1 day | +2.65% | ||
1 week | +0.60% | ||
Current month | -19.42% | ||
1 month | -5.20% | ||
3 months | -3.50% | ||
6 months | -50.56% | ||
Current year | -32.85% |
Managers | Title | Age | Since |
---|---|---|---|
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Daniel Geffken
DFI | Director of Finance/CFO | 67 | 20-10-31 |
Ali Hariri
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Rubin
BRD | Director/Board Member | 63 | 14-04-30 |
Alan Walts
BRD | Director/Board Member | 64 | 21-03-31 |
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.8058 | +2.65% | 1,985 |
24-04-25 | 0.785 | -3.09% | 1,165 |
24-04-24 | 0.81 | -1.82% | 1,251 |
24-04-23 | 0.825 | +2.80% | 6,670 |
24-04-22 | 0.8025 | +0.19% | 1,669 |
Delayed Quote OTC Markets, April 26, 2024 at 02:34 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.85% | 2.66M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ELOX Stock